No connection

Search Results

IMTX vs NVCR

IMTX
Immatics N.V.
BEARISH
Price
$10.43
Market Cap
$1.4B
Sector
Healthcare
AI Confidence
85%
NVCR
NovoCure Limited
BEARISH
Price
$12.17
Market Cap
$1.38B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
IMTX
--
NVCR
--
Forward P/E
IMTX
-5.91
NVCR
-10.44
P/B Ratio
IMTX
2.5
NVCR
4.02
P/S Ratio
IMTX
28.98
NVCR
2.11
EV/EBITDA
IMTX
-5.47
NVCR
-8.77

Profitability

Gross Margin
IMTX
-280.87%
NVCR
74.8%
Operating Margin
IMTX
-196.76%
NVCR
-21.33%
Profit Margin
IMTX
0.0%
NVCR
-20.79%
ROE
IMTX
-37.1%
NVCR
-38.89%
ROA
IMTX
-18.08%
NVCR
-9.06%

Growth

Revenue Growth
IMTX
-64.9%
NVCR
8.1%
Earnings Growth
IMTX
--
NVCR
--

Financial Health

Debt/Equity
IMTX
0.03
NVCR
0.73
Current Ratio
IMTX
11.72
NVCR
2.9
Quick Ratio
IMTX
11.07
NVCR
2.51

Dividends

Dividend Yield
IMTX
--
NVCR
--
Payout Ratio
IMTX
0.0%
NVCR
0.0%

AI Verdict

IMTX BEARISH

IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.

Strengths
Exceptional short-term liquidity with a Current Ratio of 11.72
Very low leverage with a Debt/Equity ratio of 0.03
Significant analyst price target upside (Target: $18.75 vs Price: $10.43)
Risks
Severe revenue contraction (-64.90% YoY)
Extreme operational inefficiency with Gross Margins at -280.87%
Critical Piotroski F-Score (1/9) signaling fundamental decay
NVCR BEARISH

NVCR exhibits significant financial fragility with a weak Piotroski F-Score of 3/9 and a complete lack of positive deterministic value markers (Graham/Intrinsic). While the company maintains a strong gross margin of 74.8% and healthy short-term liquidity (Current Ratio 2.90), these are offset by persistent negative profit margins and a catastrophic 5-year price decline of 93.7%. The disconnect between bullish analyst targets ($25.07) and aggressive insider selling by the CFO and COO suggests a lack of internal confidence in near-term catalysts.

Strengths
High Gross Margin (74.80%) indicating strong product value
Strong short-term liquidity with a Current Ratio of 2.90
Improving EPS growth YoY (+63.9%) despite remaining negative
Risks
Weak financial health as indicated by Piotroski F-Score (3/9)
Severe long-term value destruction (-93.7% 5-year return)
Negative operating and profit margins (-21.33% and -20.79%)

Compare Another Pair

IMTX vs NVCR: Head-to-Head Comparison

This page compares Immatics N.V. (IMTX) and NovoCure Limited (NVCR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile